Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10810342 | 0.85 | EPHX1 (0.47) | EPHX1CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL103736 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL28974203 | 0.83 | — | — | |
| SCHEMBL26139075 | 0.80 | HCRTR2 (0.35) | EPHX1HCRTR2SMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL10710365 | 0.78 | HCRTR2 (0.33) | HCRTR2SCN9AROCK2ROCK1OPRL1 | |
| SCHEMBL21807667 | 0.78 | EPHX1 (0.41) | EPHX1CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12166522 | 0.78 | EPHX1 (0.41) | EPHX1CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12735561 | 0.78 | EPHX1 (0.41) | EPHX1CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14609349 | 0.78 | EPHX1 (0.41) | EPHX1CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9747693 | 0.78 | TSHR (0.37) | HCRTR2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | EPHX1 650/4885HCRTR2 1084/4885CHRM1 778/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | EPHX1 2632/4885HCRTR2 4619/4885CHRM1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.